Multidrug-resistant tuberculosis (MDR-TB) is a serious public health problem with ultimate concern in the developing countries, including Egypt. In the global TB report issued in 2021 by World Health Organization (WHO), infection caused by the tubercle bacilli Mycobacterium tuberculosis (MTB) represents the 13 th chief cause of mortality worldwide. Effective MDR-TB control counts on the accuracy and rapidity of its diagnosis in order to start the proper treatment regimen and as a result limit the transmission of the resistant isolate. Line probe assay (LPA) and GeneXpert MTB/RIF are two WHO approved probe based molecular assays for rapid detection resistant MTB isolates via screening its nucleic acid for any mutations. For the purpose of finding mutations linked to rifampicin resistance using DNA probes, both techniques focus on the same 81 bp Rifampicin Resistance Determining Region. Line probe assay can detect both rifampicin and isoniazid resistance, thus can detect isoniazid mono resistant isolates, which requires special management protocol, in addition to detecting MDR-TB isolates as well with high sensitivity and specificity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.